CAS: 486424-20-8; 3-Amino-6-(4-((4-Methylpiperazin-1-yl)Sulfonyl)Phenyl)-N-(Pyridin-3-yl)Pyrazine-2-Carboxamide

该化合物是一种化学化合物,其结构复杂,包括一个丙烯酸环,一个碳本甲酰胺组和一个氟化烃.该化合物由于其生物活性特性,通常被归类为药物中间体或潜在药物候选体.它显示出一系列特性,包括有机溶剂溶性以及与生物目标的潜在相互作用,因此对药用化学感兴趣. 磺酰基和氟化烃环的存在表明,它可能具有特定的药理活动,可能与其与...

结构式图片

欧盟法规

C&L通报

上下游产品

methyl 3-amino-6-bromopyrazine-2-carboxylate pyridin-3-ylamine 1-((4-bromophenyl)sulfonyl)-4-methylpiperazine 4-[(4-methylpiperazin-1-yl)sulfonyl]phenylboronic acid

合成工艺路线路线简述

    1-(4-溴苯基磺酰基)-4-甲基哌嗪置于正丁基锂,1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物,水,Silica Gel,Sodium Carbonate体系中,用 四氢呋喃,乙醇,水,甲苯 作为反应溶剂,化学反应 18.5H,反应生成 3-氨基-6-[4-(4-甲基哌嗪-1-基)磺酰基苯基]-N-吡啶-3-基吡嗪-2-羧酰胺
    参考文献:Discovery Of Novel Potent And Highly Selective Glycogen Synthase Kinase-3β (Gsk3β) Inhibitors For Alzheimer's Disease: Design,Synthesis,And Characterization Of Pyrazines
    标题:Discovery Of Novel Potent And Highly Selective Glycogen Synthase Kinase-3β (Gsk3β) Inhibitors For Alzheimer's Disease: Design,Synthesis,And Characterization Of Pyrazines
    摘要:Glycogen Synthase Kinase-3 Beta,Also Called Tau Phosphorylating Kinase,Is A Proline-Directed Serine/threonine Kinase Which Was Originally Identified Due To Its Role In Glycogen Metabolism. Active Forms Of Gsk3 Beta Localize To Pretangle Pathology Including Dystrophic Neuritis And Neurofibrillary Tangles In Alzheimer'S Disease (Ad) Brain. By Using A High Throughput Screening (Hts) Approach To Search For New Chemical Series And Cocrystallization Of Key Analogues To Guide The Optimization And Synthesis Of Our Pyrazine Series,We Have Developed Highly Potent And Selective Inhibitors Showing Cellular Efficacy And Blood-Brain Barrier Penetrance. The Inhibitors Are Suitable For In Vivo Efficacy Testing And May Serve As A New Treatment Strategy For Alzheimer'S Disease.
    DOI:10.1021/jm201724M

    海关参考信息

    专利信息


    专利号:WO-2008080986-A1
    优先权日:2006-12-28
    标 题 :Furan derivatives, method of synthesis and uses thereof
    发明人:MARTINEZ GIL ANA; MEDINA PADILLA MIGUEL; FALL DIOP YAGAMARE; GOMEZ PACIOS GENEROSA; PEREZ VAZQUEZ MANUEL; MARTIN APARICIO ESTER; FUERTES HUERTA ANA; DEL MONTE MILLAN MARIA; NAVARRO RICO MARIA LUISA; PEREZ PUERTO MARIA JOSE
    权利人:NEUROPHARMA SA; MARTINEZ GIL ANA; MEDINA PADILLA MIGUEL; FALL DIOP YAGAMARE; GOMEZ PACIOS GENEROSA; PEREZ VAZQUEZ MANUEL; MARTIN APARICIO ESTER; FUERTES HUERTA ANA; DEL MONTE MILLAN MARIA; NAVARRO RICO MARIA LUISA; PEREZ PUERTO MARIA JOSE
    摘要:The present invention relates to furan derivatives of formula (I), their method of synthesis and uses thereof. Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3β, GSK-3 β, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.

    专利号:EP-1939191-A1
    优先权日:2006-12-28
    标题 :Furan derivatives, method of synthesis and uses thereof

    专利号:WO-2008080988-A2
    优先权日:2006-12-28
    标题:Cyclopentanone derivatives, method of synthesis and uses thereof

    专利号:EP-1939192-A1
    优先权日:2006-12-28
    标 题:Cyclopentanone derivatives, method of synthesis and uses thereof
    上海泽涵生物医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zehanbiopharma.com
    电话: 021-61350663 13052117465👤
    📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

    销售电话:021-61350663 13052117465
    邮箱:sales@zehanbiopharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Gilmour PS, O'Shea PJ, Fagura M, Pilling JE, Sanganee H, Wada H, Courtney PF, Kavanagh S, Hall PA, Escott KJ. Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats. Toxicol Appl Pharmacol. 2013 Oct 15;272(2):399-407. doi: 10.1016/j.taap.2013.07.001. Epub 2013 Jul 18. doi: 10.1016/j.bone.2013.01.019. Epub 2013 Jan 19. doi: 10.1016/j.bone.2011.11.007. Epub 2011 Nov 25.

    合成参考文献


    参考文献:10.1124/mol.119.115964
    摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
    参考文献:10.1007/978-3-031-10220-2_4
    摘要:Oak U, Khare T. Nanoparticle Functionalization: Approaches and Applications. 2022. In: Nanotechnology in the Life Sciences.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知